IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
REQUEST FOR FILING NATIONAL PHASE OF
PCT APPLICATION UNDER 35 U.S.C. 371 AND 37 CFR 1.494 OR 1.495

To: Hon. Commissioner of Patents
Washington, D.C. 20231

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

Atty Dkt: PM 275443 /C90.04/Q
M# /Client Ref.

From: Pillsbury Madison & Sutro LLP, IP Group:

Date: January 5, 2001

This is a **REQUEST** for **FILING** a PCT/USA National Phase Application based on:

1. International Application	2. International Filing Date	3. Earliest Priority Date Claimed
PCT/GB99/02165	06 JUL 1999	07 JUL 1998
⇧ country code	Day MONTH Year	Day MONTH Year (use item 2 if no earlier priority)

4. Measured from the earliest priority date in item 3, this PCT/USA National Phase Application Request is being filed within:

(a) ☐ 20 months from above item 3 date (b) ☒ 30 months from above item 3 date,

(c) Therefore, the due date (unextendable) is January 7, 2001

5. Title of Invention METHOD OF REDUCING OR PREVENTING MALODOUR

6. Inventor(s) WILSON, Craig et al

Applicant herewith submits the following under 35 U.S.C. 371 to effect filing:

7. ☒ Please immediately start national examination procedures (35 U.S.C. 371 (f)).

8. ☒ **A copy of the International Application** as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (file if in English but, if in foreign language, file only if not transmitted to PTO by the International Bureau) including:

a. ☒ Request;
b. ☒ Abstract;
c. 13 pgs. Spec. and Claims;
d. _____ sheet(s) Drawing which are ☐ informal ☐ formal of size ☐ A4 ☐ 11"

9. ☒ **A copy of the International Application has been transmitted by the International Bureau.**

10. **A translation of the International Application** into English (35 U.S.C. 371(c)(2))
a. ☐ is transmitted herewith including: (1) ☐ Request; (2) ☐ Abstract;
(3) _____ pgs. Spec. and Claims;
(4) _____ sheet(s) Drawing which are:
☐ informal ☐ formal of size ☐ A4 ☐ 11"
b. ☐ is not required, as the application was filed in English.
c. ☐ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.
d. ☐ Translation verification attached (not required now).

11. ☒ **PLEASE AMEND** the specification before its first line by inserting as a separate paragraph:
a. ☒ --This application is the national phase of international application PCT/GB99/02165 filed July 6, 1999 which designated the U.S, and that international application ☒ was ☐ was not published under PCT Article 21(2) in English.--
b. ☐ --This application also claims the benefit of U.S. Provisional Application No. 60/_____, filed _____ .--

12. ☐ Amendments to the claims of the International Application **under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., before 18th month from first priority date above in item 3, are transmitted herewith (file only if in English) including:**

13. ☒ PCT Article 19 claim amendments (if any) have been transmitted by the International Bureau

14. ☐ Translation of the amendments to the claims **under PCT Article 19 (35 U.S.C. 371(c)(3)), i.e., of claim amendments** made before 18th month, **is attached (required by 20th month from the date in item 3 if box 4(a) above is X'd, or 30th month if box 4(b) is X'd, or else amendments will be considered canceled).**

15. **A declaration of the inventor** (35 U.S.C. 371(c)(4))
a. ☒ is submitted herewith ☒ Original ☐ Facsimile/Copy
b. ☐ is not herewith, but will be filed when required by the forthcoming PTO Missing Requirements Notice per Rule 494(c) if box 4(a) is X'd or Rule 495(c) if box 4(b) is X'd.

16. **An International Search Report (ISR):**
a. Was prepared by ☒ European Patent Office ☐ Japanese Patent Office ☐ Other
b. ☒ has been transmitted by the international Bureau to PTO.
c. ☒ copy herewith (2 pg(s).) ☒ plus Annex of family members (1 pg(s).).

17. **International Preliminary Examination Report** (IPER):
a. ☒ has been transmitted (if this letter is filed after 28 months from date in item 3) in English by the International Bureau with Annexes (if any) in original language.
b. ☒ copy herewith in English.
c.1 ☒ IPER Annex(es) in original language ("Annexes" are amendments made to claims/spec/drawings during Examination) including attached amended:
c.2 ☐ Specification/claim pages #14 claims #13 - 15
Dwg Sheets #
d. ☐ Translation of Annex(es) to IPER **(required by 30th month due date, or else annexed amendments will be considered canceled).**

18. **Information Disclosure Statement** including:
a. ☒ Attached Form PTO-1449 listing documents
b. ☒ Attached copies of documents listed on Form PTO-1449
c. ☒ A concise explanation of relevance of ISR references is given in the ISR.

19. ☒ **Assignment** document and Cover Sheet for recording are attached. Please mail the recorded assignment document back to the person whose signature, name and address appear at the end of this letter.

20. ☐ Copy of Power to IA agent.

21. ☐ **Drawings** (complete only if 8d or 10a(4) not completed): ___ sheet(s) per set: ☐ 1 set informal; ☐ Formal of size ☐ A4 ☐ 11"

22. Small Entity Status ⌀ ☒ is **Not** claimed ☐ is claimed (**pre**-filing confirmation required)
22(a) _____ (No.) Small Entity Statement(s) enclosed (since 9/8/00 Small Entity Statements(s) not essential to make claim)

23. **Priority** is hereby claimed under 35 U.S.C. 119/365 based on the priority claim and the certified copy, both filed in the International Application during the international stage based on the filing in (country) Great Britain of:

	Application No.	Filing Date		Application No.	Filing Date
(1)	9814653.3	07 JUL 1998	(2)		
(3)			(4)		
(5)			(6)		

a. ☒ See Form PCT/IB/304 sent to US/DO with copy of priority documents. If copy has not been received, please proceed promptly to obtain same from the IB.
b. ☒ Copy of Form PCT/IB/304 attached.

24. Attached:

RE: USA National Filing of PCT/GB99/02165

25. **Preliminary Amendment:**

25.5 Per Item 17.c2, **cancel original** pages #_____, claims #_____, Drawing Sheets #

26. **Calculation of the U.S. National Fee (35 U.S.C. 371 (c)(1)) and other fees is as follows:**

Based on amended claim(s) per above item(s) ☐ 12, ☐ 14, ☒ 17, ☐ 25, ☐ 25.5 (hilite)

Total Effective Claims	18	minus 20 =	0	x $18/$9	=	$0	966/967
Independent Claims	8	minus 3 =	5	x $80/$40	=	$400	964/965
If any proper (ignore improper) Multiple Dependent claim is present,				add$270/$135		+270	968/969

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(4)): →→ **BASIC FEE REQUIRED, NOW** →→→→

A. If country code letters in item 1 are **not** "US","BR","BB","TT","MX","IL" "NZ", "IN" or "ZA"

See item 16 re:

1. Search Report was not prepared by EPO or JPO - - - - - - - - - add$1000/$500 960/961
2. Search Report was prepared by EPO or JPO - - - - - - - - - - - - add$860/$430 +860 970/971

SKIP B, C, D AND E UNLESS country code letters in item 1 are "US","BR","BB","TT","MX","IL", "NZ", "IN" or "ZA"

(X) →	☐ B.	If USPTO did not issue both International Search Report (ISR) and (if box 4(b) above is X'd) the International Examination Report (IPER), -	add$970/$485	+0 960/961
(only) (one) → (of) (these) (4) → (boxes)	☐ C.	If USPTO issued ISR but not IPER (or box 4(a) above is X'd), -	add$710/$355	+0 958/959
	☐ D.	If USPTO issued IPER but IPER Sec. V boxes not all 3 YES, -	add$690/$345	+0 956/957
→	☐ E.	If international preliminary examination fee was paid to USPTO and Rules 492(a)(4) and 496(b) satisfied (IPER Sec. V all 3 boxes YES for all claims), - - - - - - - - - - - - -	add $100/$50	+0 962/963
27.			**SUBTOTAL =**	$1530

28. If Assignment box 19 above is X'd, add Assignment Recording fee of ----$40 +40 (581)

29. Attached is a check to cover the - **TOTAL FEES** $1570

Our Deposit Account No. 03-3975
Our Order No. 41301 (C#) | 275443 (M#)

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 and 492 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.
This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed

Pillsbury Winthrop LLP
Intellectual Property Group

1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
Tel: (202) 861-3000
Atty/Sec: PNK/sdm

By Atty: Paul N. Kokulis **Reg. No. 16773**
Sig: 
Fax: (202) 822-0944
Tel: (202) 861-3503

NOTE: File in duplicate with 2 postcard receipts (PAT-103) & attachments.

APPLICATION UNDER UNITED STATES PATENT LAWS

Atty. Dkt. No. PM 275443
(M#)

Invention: METHOD OF REDUCING OR PREVENTING MALODOUR

Inventor (s): WILSON, Craig, S.
MINHAS, Tony
BEHAN, John M.

Pillsbury Winthrop LLP
Intellectual Property Group
1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
Attorneys
Telephone: (202) 861-3000

This is a:

- ☐ Provisional Application
- ☐ Regular Utility Application
- ☐ Continuing Application
  - ☒ The contents of the parent are incorporated by reference
- ☒ PCT National Phase Application
- ☐ Design Application
- ☐ Reissue Application
- ☐ Plant Application
- ☐ Substitute Specification
  Sub. Spec Filed _____
  in App. No. _____ / _____
- ☐ Marked up Specification re
  Sub. Spec. filed _____
  In App. No _____ / _____

SPECIFICATION

METHOD OF REDUCING OR PREVENTING MALODOUR

This invention relates to perfume components, mixtures thereof and perfume compositions, to personal products and detergent products containing such perfumes, and to a method and the use of such perfumes and products to deliver a deodorant effect.

In particular, it relates to perfume components, mixtures thereof, and perfume compositions for inhibiting the production of odorous metabolites by topically applying to human skin perfumery components capable of inhibiting the production of body malodour caused by micro-organisms comprising corynebacteria, preferably by selectively inhibiting those corynebacteria capable of catabolising fatty acids.

It is well known that freshly secreted sweat is odourless and that body malodour is the result of a biotransformation of the sweat by micro-organisms living on the surface of the skin to produce volatile odoriferous compounds.

There are three types of personal product routinely used to combat body malodour: perfumes, antiperspirants and deodorants.

Perfumes may simply mask body malodour. However perfume compositions have been disclosed which exhibit a deodorant action. EP-B-3172, EP-A-5618, US-A-43044679, US-A-4322308, US-A-4278658, US-A-4134838, US-A-4288341 and US-A-4289641 all describe perfume compositions which exhibit a deodorant action when applied to human skin or when included in a laundry product used to launder textiles.

Antiperspirants work by blocking the sweat glands thereby reducing perspiration.

Antimicrobial agents used in deodorants are designed to reduce the population of micro-organisms living on the surface of the skin. Typical agents of this nature include ethanol and Triclosan (2,4,4'-trichloro-2'-hydroxy-diphenyl ether) which are well known to exert antimicrobial effects. The use of common deodorant actives results in a non-selective antimicrobial action exerted upon most of the skin's natural microflora. This is an undesirable side effect of such deodorant formulations.

Many disclosures describe compositions comprising antimicrobials which are designed to eliminate malodour by sub-lethally reducing the microflora population.

WO 95/16429 (Henkel) describes deodorant compositions comprising fat soluble partial esters of hydroxy carboxylic acids.

WO 95/07069, WO 91/11988 and WO 91/05541 (all Gillette) describe deodorant compositions comprising inhibitors of pyridoxal phosphate dependent amino acid lyase.

WO 94/14934 (Unilever) describes a method for reducing the perceptibility of an odoriferous substance using an antibody or antibody fragment. Such antibodies could be used in deodorant compositions.

WO 93/07853 (Monell) describes the use of mimics of the odoriferous compound 3-methyl-2-hexenoic acid to reduce body malodour.

DD 29 39 58 (Medezinische Fakultaet (Charite) der Humboldt Universitaet zu Berlin) describes the use of lipoxygenase inhibitors to act biochemically to reduce sweat production or to inhibit, to various degrees, the action of skin bacteria or their enzymes on the

decomposition of sweat to form unpleasant-smelling substances.

DE 43 43 265 (Henkel) describes deodorant compositions comprising saturated dioic acid (C3 - C10) esters. It is claimed that the active inhibits a sweat decomposing esterase and the compositions are said not to disturb the skin's natural microflora.

DE 43 43 264 (Henkel) describes the use of lipid-soluble partial esters of hydroxy carboxylic acids in deodorant compositions.

Some disclosures describe the use of antimicrobial substances which are selective against odour producing bacteria.

WO 90/15077 (Gillette) describes the use of antibodies to a carrier or transport protein of coryneform and staphylococci. It is disclosed that these bacteria types have an amino acid lyase enzyme which is responsible for the formation of malodour.

DE 43 39 605 (Beiersdorf) describes the use of deodorising mixtures of alpha-omega alkanedioic acids and fatty acid partial glycerides of unbranched fatty acids which may be present in a suitable cosmetic vehicle to combat Gram-positive, particularly coryneform, bacteria.

Woolwax acids have also been disclosed in the following Beiersdorf publications as deodorant actives in combination with:

-alpha-omega alkanedioic acids (DE 43 24 219);

-partial glycerides of unbranched fatty acids (DE 43 09 372); or

-monocarboxylic acids, especially unbranched fatty acids (DE 43 05 889).

Each combination is described as suitable to combat Gram-positive, especially coryneform bacteria.

DE 4237081 (Beiersdorf) describes deodorant compositions comprising monocarboxylic acid diglycerides and/or triglycerides. The compositions are said to be suitable against Gram-positive, especially coryneform, bacteria.

EP-A-0 697 213 (Beiersdorf) describes the selective reduction of coryneform bacteria using a mixture of:

-lauric acid;

-one other fatty acid C6 - C20 (one of which must be at least C12);

-glyceryl monocaprate/glyceryl monocaprylate;

-without the use of ethoxylated glyceryl fatty acid esters and propoxylated glyceryl fatty acid esters;

which has a pH of less than 8.

WO 94/07837 (Unichema) describes certain novel unsaturated dioic acids having between 8 and 22 carbon atoms. Also described is their potential use to treat malodour.

EP-A-0 750 903 (Cooperatie Cosun UA) discloses deodorant compositions comprising sugar-fatty acid esters. The actives are described as being selective towards odour causing micro-organisms. These odour-causing micro-organisms are said to be the Corynebacterium varieties known as lipophilic diphtheroids such as *Corynebacterium xerosis* and *C. minutissimum*.

Coryneform is a designation of a large ill-defined group of bacteria. The diverse genera that have been included with the coryneforms include Actinomyces, Arachnia, Arcanobacterium, Arthrobacter, bacterionema, Bifidobacterium, Brevibacterium, Cellulomonas, Corynebacterium, Eyrsipelothrix, Eubacterium, Kurthia, Listeria, Mycobacterium, Nocardia, Oerskovia, Propionibacterium, Rhodococcus and Rothia.

It is clear that the majority of previous disclosures in this area have been aimed at antibacterial or bacteriostatic effects towards the whole skin flora or selected species.

Without being bound by theory we believe that the *Corynebacterium* genus can be subdivided into two subgroups according to ability to catabolise fatty acids. We further believe that one of these subgroups, hereinafter referred to as "Corynebacteria A", which is capable of catabolising fatty acids, contributes strongly to the formation of body malodour, in particular axillary malodour. The other subgroup, hereinafter referred to as "Corynebacteria B", which catabolises fatty acids much less so or not at all, contributes much less or even not at all to malodour formation. We also believe that it is possible to selectively inhibit the generation of odorous metabolites by Corynebacteria A.

The deodorants available on the market tend to be insufficiently effective and/or substantially reduce the numbers of all bacteria in the microflora indiscriminately. The present invention offers the opportunity to provide deodorant products which for many females will substantially reduce malodour formation while inhibiting only a minor portion of the microflora. For many males malodour formation can be substantially reduced or even largely eliminated by inactivating the Corynebacteria A.

Furthermore, we have found a range of perfume components capable of selectively inactivating Corynebacteria A, while leaving other bacteria, notably Corynebacteria B much less affected or even not notably affected at all. Significant deodorant action can be obtained by the action of these components singly or in combination.

Accordingly, the invention provides a cosmetic method for reducing or preventing body malodour by topically applying to human skin a composition comprising an active agent capable of inactivating body malodour-causing micro-organisms comprising corynebacteria, wherein the agent is a perfume component which is capable of inactivating the corynebacteria capable of catabolising fatty acids.

The invention also provides the use of a perfume component to inactivate the corynebacteria capable of catabolising fatty acids.

The invention further provides the use of a perfume composition, comprising at least 30% by weight of one or more perfume components capable of inactivating the corynebacteria capable of catabolising fatty acids, to reduce body malodour.

The invention further provides the use of a deodorant product comprising a perfume component to reduce body malodour by inactivating the corynebacteria capable of catabolising fatty acids.

The invention further provides a perfume composition comprising at least 30% by weight of one or more of the following perfume components:

(Z)-3,4,5,6,6-pentamethylhept-3-en-2-one, mixtures of diethyl- and dimethyl-cyclohex-2-en -1-one, citronellol, 2-methyl-3-(4-(1-methylethyl)phenyl)propanal, (2-(methyloxy)-4-propyl -1-benzenol), diphenylmethane, tetrahydrolinalol, 4-(4-methyl-3-pentenyl)cyclohex-3-ene -1-carbaldehyde, 3-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(1,3-benzodioxol -5-yl)-2-methylpropanal, α-ionone, β-ionone, tricyclo[5.2.1.0,2,6]dec-4-en-8-yl ethanoate, 4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde, 3-(4-hydroxy-4-methylpentyl) -cyclohex-3-enecarbaldehyde, methyl iso-eugenol, 2-(1,1-dimethylethyl)cyclohexyl ethanoate, 4-(1,1-dimethylethyl)cyclohexylethanoate, 4-methyl-2-(2-methylprop-1-enyl) tetrahydropyran, and a deodorant product comprising such a perfume composition.

The invention still further provides a method of producing a perfume composition which comprises (i) evaluating perfume components on the ability to inhibit fatty acid metabolism in corynebacteria, (ii) selecting perfume components on the ability to sub-lethally inhibit fatty acid metabolism in corynebacteria, and (iii) mixing together two or more of said selected perfume components, optionally with other perfume components.

The term "perfume component" is used herein to represent a material which is added to a perfume to contribute to the olfactive properties of the perfume. A perfume component can be acceptably employed to provide odour contributions to the overall hedonic performance of products. Typically, a perfume component will be generally recognised as possessing odours in its own right, will be relatively volatile and often has a molecular weight within the range 100 to 300. Typical materials which are perfume components are described in "Perfume and Flavour Chemicals", Volumes I and II (Steffan Arctander, 1969). A perfume composition will contain a number of individual perfume components, and optionally a suitable diluent. The concentration of perfume components referred to herein is relative to the total concentration of perfume components present in the composition, ie excludes any diluent.

The perfume components used in the present invention are capable of inactivating Corynebacteria, preferably selectively inactivating Corynebacteria A. By inactivate is meant any sub-lethal effect resulting in a reduction or elimination of the production of odoriferous metabolites, eg by modification of bacterial metabolism, such as fatty acid metabolism. The sub-lethal effect of a perfume component preferably occurs at concentrations below its minimum inhibitory concentration, determined as decribed in Example 2 below.

In particular, by sub-lethal is meant a significant inhibition of metabolism, e.g. pentadecanoic acid utilisation (at least 60% inhibition), preferably without concomitant reductions in cell viability (not more than 1 $\log_{10}$ CFU/ml reduction) and glucose utilisation (not more than 10% reduction).

The perfume components used in the present invention may be incorporated into deodorant products which include, but are not limited to, body deodorants and antiperspirants including roll ons, gel products, stick deodorants, antiperspirants, shampoos, soap shower gels, talcum powder, hand cream, skin conditioners, sunscreen, sun tan lotion, skin and hair conditioners.

The perfume components may also be usefully employed for deodorant properties by incorporation into other products, for example, in laundry and household products such as

rinse conditioners, household cleaners and detergent cleaners. The perfume components can be incorporated into textiles themselves during their production using techniques known in the art, to provide deodorant protection.

It is postulated that the preferred selective inhibition of Corynebacteria A is achieved by inhibiting the metabolic pathways of the Corynebacteria A which leads to a reduction in the production of malodorous metabolites. The inhibition of the metabolic pathway of Corynebacteria A is more important than the inhibition of the metabolic pathway of Corynebacteria B, as only the Corynebacteria A are capable of producing malodorous products.

In a preferred method according to the invention, perfume components which selectively inhibit the metabolic pathway of only those corynebacteria capable of catabolising fatty acids are used, by which is meant inactivating Corynebacteria A to a significantly higher degree than Corynebacteria B. Preferably, it means inactivating Corynebacteria A to a significantly higher degree than the majority, preferably at least 75%, more preferably at least 90% of bacteria, other than Corynebacteria A constituting the skin microflora.

The levels of perfume materials used in a skin product may lead to general bacteriostatic and bactericidal effects. A skilled person responsible for formulating a finished product will be able to adjust the level to produce the desired effect in the final product.

The perfume components employed in the present invention are more active with Corynebacteria A than with other bacteria constituting the axillary microflora, including Corynebacteria B, when considering the selective inhibition of the metabolic pathway of the bacteria, particularly in respect of fatty acid metabolism.

The active perfume components preferably selectively inhibit the metabolic pathway of Corynebacteria A, leading to a reduction of malodorous compounds, producing a deodorant effect in consumer products. In a preferred method according to the invention, an Odour Reduction Value, measured as described in Example 4, of at least 10%, more preferably at least 30%, and particularly at least 50% is obtained. The active components may be mixed with other perfume components to deliver perfumes or perfume compositions with the desired deodorant and hedonistic properties. To deliver high deodorant effects the active components preferably comprise 30% or more of the total perfume formulation by weight, more preferably at least 40% and particularly at least 60%. A deodorant product preferably comprises at least 0.05% to 4%, more preferably 0.1% to 2% by weight of the active perfume components. Preferred actives include the following perfume components.

(Z)-3,4,5,6,6-pentamethylhept-3-en-2-one (Acetyl di iso amylene)

Mixture of diethyl- and dimethyl-cyclohex-2-en-1-one (Azarbre)

Citronellol

2-methyl-3-(4-(1-methylethyl)phenyl)propanal (Cyclamen aldehyde)

(2-(methyloxy)-4-propyl-1-benzenol) (Dihydroeugenol)

Diphenylmethane

Tetrahydrolinalol

4-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde (Empetaal)

3-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde (Empetaal)

3-(1,3-benzodioxol-5-yl)-2-methylpropanal (Helional)

α- and β-Ionone and mixtures thereof (Ionone)

tricyclo[5.2.1.0 2,6]dec-4-en-8-yl ethanoate (Jasmacylene)

4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde (Lyral)

3-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde (Lyral)

Methyl iso-eugenol

2-(1,1-dimethylethyl)cyclohexyl ethanoate (Ortholate)

4-(1,1-dimethylethyl)cyclohexyl ethanoate (Ortholate)

4 -Methyl-2-(2-methylprop-1-enyl)tetrahydropyran (Rose oxide)

A perfume composition for use in the present invention preferably comprises at least 5, more preferably at least 10, and particularly at least 15 of the above perfume components.

The invention is illustrated by the following examples.

EXAMPLE 1

A demonstration of fatty acid catabolism in an isolated pure culture of Corynebacterium A deposited as NCIMB 13590 (deposited under the Budapest Treaty with National Collections of Industrial and Marine Bacteria Ltd, 23 St Machar Drive, Aberdeen Scotland, UK on 28 June 1999) was determined *in vitro* using the method given below:

The *in vitro* model system, reproducing fatty acid catabolism by axillary bacteria, consisted of 250 ml baffled shake flasks, to which were added 30 ml semi-synthetic medium (see below) supplemented with fatty acid substrate (2.0 mg/ml pentadecanoic acid) This system was employed to evaluate selected potential deodorant actives (see below). Flasks were inoculated with fresh bacterial biomass, pre-grown for 24 h in TSBT (see below), to give starting optical densities (A_{590}) of 1.0 - 2.0. Following inoculation, flasks were incubated aerobically at 35°C, with agitation (130 rpm), and analysed after 24 h. Culture viability/purity was determined by TVC analysis on TSAT plates (see below) following serial dilution in quarter-strength Ringers solution.

Fatty acid levels in the flasks were determined by capillary gas chromatography (GC) analysis. Initially, 5.0 ml aliquots from each flask were rapidly transferred into universal tubes; an internal standard (1.0 mg/ml lauric acid) was added to each universal tube and the culture medium was acidified (pH ~2) by the addition of hydrochloric acid. Liquid-liquid extraction was then carried out using 2 vol (10 ml) ethyl acetate; organic and aqueous phases were resolved by centrifugation (2000 rpm, 3 min). 2.0 ml of each organic (upper) phase was then transferred to a sampling tube prior to analysis on a Perkin Elmer 8000 (Series 2) GC fitted with a 15 m x 0.32 mm (internal diameter) FFA (nitroterephthalic acid modified PEG/siloxane copolymer) fused silica capillary column (film thickness 0.25 mm) (Quadrex). This column was attached to the split splitless injector and flame ionisation detector (FID) of the GC ; injector and detector temperatures were each 300°C. Carrier gas for the column was helium (6.0 psi), while hydrogen (17 psi) and air (23 psi) were supplied the FID. The temperature programme for fatty acid analysis was 80°C (2 min); 80-250°C (20°C/min); 250°C (5 min). Sample size for

injection was 0.5 -1.0 µl. Fatty acid levels in the flasks were quantified by comparison of peak areas with known levels of both internal (lauric acid) and external (pentadecanoic acid) standards.

EXAMPLE 2

The minimum inhibitory concentration of perfume components was determined by the following method.

A fresh culture of of the test inoculum (Corynebacteria xerosis NCTC 7243 (National Collection of Type Cultures, Public Health Laboratory Service, Central Public Health Laboratory , 61 Colindale Avenue, London)) diluted in sterile 0.1% special peptone solution to give a concentration of approximately 10^5 cfu/ml was prepared

Test samples were diluted in sterile trptone soya broth (TSB) Each row of the microtitre plate (labelled A - H) was allocated to one sample, i.e. eight samples per plate. Row 8 (H) contained only TSB for use as a bacterial control to indicate level of turbidity in the absence of test material. Aseptically 200 µl of the initial dilution was transferred to the 1st and 7th well of the appropriate row. All other test wells were filled with 100 µl of sterile TSB using an 8 channel pipette. The contents of all wells in column 1 were mixed by sucking samples up and down pipette tips before 100 µl was transferred to column 2. The same sterile pipette tips can be used to transfer 100 µl of each well in column 7 in to the appropriate well in column 8. Tips were discarded into disinfectant solution. Using fresh sterile tips the process was repeated by transferring 100 µl from column 2 into column 3 (and 8 into 9). The process was continued until all wells in columns 6 and 12 contained 200 µl. After mixing 100 µl was discarded from wells in these columns to waste.

To all wells 100 µl of pre-diluted test culture was added giving 200 µl final volume in each well.

A blank plate was prepared for each set of samples using the above protocol except 100 µl of sterile 0.1% peptone was added instead of bacterial culture.

Plates were sealed using autoclave tape and incubated overnight at 35° C.

The reader was preset to gently agitate the plates to mix the contents before reading absorbance at 540 nm. The control plate for each set of samples was read first. The reader was then reprogrammed to use the control readings to blank all other plate readings of the set of test materials (i.e. removing turbidity due to perfume and possible colour changes during incubation) thus only printing out absorbances due to turbidity resulting from bacterial growth. Limits were set so that degrees of turbidity were given a rating.

The MIC was taken as the level of sample required to inhibit growth completely (change in absorbance < 0.2).

EXAMPLE 3

Demonstration of sub-lethal inactivation of fatty acid catabolism was performed with the following in *vitro* method.

Prior to inoculation, flasks were supplemented with selected perfume components, at a range of concentrations (eg 500 ppm and 1000 ppm) below their predetermined minimum inhibitory concentration, to determine their ability to sub-lethally inhibit fatty acid catabolism by

Corynebacteria A (NCIMB 13590). Stock active solutions/emulsions were prepared in semi-synthetic medium (see below), emulsions were formed by ultra-homogenisation at 24,000 rpm for ~1 min. At the end of each experiment, viability and fatty acid levels in the experimental flasks were compared to those in a control flask. Sub-lethal inhibition of fatty acid catabolism was defined as significant inhibition of pentadecanoic acid utilisation, without concomitant reductions in cell viability.

Composition of Tween-supplemented Tryptone soya broth/agar (TSBT, TSAT) used for growth/maintenance of axillary bacteria (g/l) :Tryptone soya broth (30.0), Yeast extract (10.0), Tween 80 (1.0), ± Agar (20.0). Composition of semi-synthetic medium used in laboratory systems simulating fatty acid catabolism by axillary bacteria (g/l): KH_2PO_4 (1.6), $(NH_4)_2HPO_4$ (5.0), Na_2SO_4 (0.38), Yeast Nitrogen Base (Difco) (3.35), Yeast Extract (0.5), Tween 80 (0.2), Triton X-100 (0.2), $MgCl_2.6H_20$ (0.5), Pentadecanoic acid (2.0).

The results below show the perfume components that are active and inactive with regard to the inhibition of fatty acid metabolism in Corynebacteria A.

Inhibition of long chain fatty acid metabolism observed	**No inhibition of long chain fatty acid metabolism observed**
(Z)-3,4,5,6,6-pentamethylhept-3-en-2-one	Aldehyde C11
Mixture of diethyl- and dimethyl-cyclohex-2-ene-1-one	Anisic Aldehyde
2-methyl-3-(4-(1-methylethyl)phenyl) propanal	Caryophyllene
(2-(methyloxy)-4-propyl-1-benzenol)	Cinnamic alcohol
Diphenylmethane	2H-2-chromenone
4-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde	
3-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde	Florocyclene 3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-6-yl propanoate
3-(1,3-benzodioxol-5-yl)-2-methylpropanal	4,6,6,7,8,8-hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[gamma]isochromene
Mixture of alpha and beta ionone	Hexyl cinnamic aldehyde
4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene carbaldehyde	
3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene carbaldehyde	hexyl 2-hydroxy-1-benzene carboxylate

Methyl-iso-eugenol	Iso-e-super
2-(1,1-dimethylethyl)cyclohexyl ethanoate	Lilial
4-Methyl-2-(2-methylprop-1-enyl)-tetrahydropyran	Thyme red

EXAMPLE 4

The following are typical formulations of deodorant products which comprise a perfume or perfume component capable of inhibiting the production of body malodour by micro-organisms comprising Corynebacteria. These formulations are made by methods common in the art.

Deodorant Sticks

Ingredient	Content (% by weight)	
	Formulation 1A	Formulation 1B
Ethanol		8
Sodium Stearate	7	6
Propylene glycol	70	12
Perfume	1.5	2
PPG-3 Myristyl ether		28
PPG-10 Cetyl ether		10
Cyclomethicone		34
Silica		
Water	21.5	

Aerosols

Ingredient	content % by weight	
	Formulation 2A	Formulation 2B
Ethanol B	up to 100	
Propylene glycol	as required	
Perfume	2.5	1.5
Chlorhydrol microdry		31.8
Silicone Fluid DC344		up to 100
Bentone gel IPP		13.65

Irgasan DP300	0.03	
Dimethyl ether	20	
Concentrate		22
Water	23	

Roll ons

Ingredient	Content % by weight	
	Formulation 3A	Formulation 3B
Ethanol	to 100%	60
Klucel MF		0.65
Cremphor RM410		0.5
Perfume	0.5	1
AZTC*	20	
Cyclomethicone	68	
Dimethicone	5	
Silica	2.5	
Water		37.85

* Aluminium zirconium tetrachlorohydro glycinate

Two perfume compositions embodying this invention were made and tested for deodorant action in an underarm product, using an Odour Reduction Value test generally as described in US-A-4278658, but with the substitution of the perfumed soap by perfumed roll-on product, using the formulation described in Formulation 3B. These perfume compositions and the method for an Odour Reduction Value test are set out below.

	Composition by %	
	Perfume A	Perfume B
Acetyl di iso amylene	10	7
Adoxal		0.5
Amberlyn super PM 577 10%DPG	3	
Azarbre	3.5	
Benzyl acetate extra	8	8
Benzyl salicylate	8	12

Cassis base		5
Citral lemarome		3
Citronellol pure		15
Cyclamen aldehyde		5
Dihydro jasmone	0.5	
Diphenyl methane	3	
Dupical		0.3
Helional		4
Ionone	15	
Jasmacyclene	3	
Ligustral 10%DPG AAA 1486	3	
Lyral	8	15
Methyl iso eugenol	5	
Methyl octyl acetaldehyde 10%DPG AA1918		2
Ortholate		8
Para tert butyl cyclo hexyl acetate	12	
Phenyl ethyl alcohol	12	13
Roseacetone	6	2.2

The Odour Reduction Value test was carried out using a panel of 40 Caucasian male subjects. A standard quantity (approximately 0.4g) of a roll-on product containing one of the perfume compositions or an unperfumed control was applied to the axillae of the panel members in accordance with a statistical design.

After a period of five hours the axillary odour was judged by three trained female assessors who scored the odour intensity on the 0 to 5 scale, as shown below.

Score	Odour level	Conc. of aqueous isovaleric acid (ml/l)
0	No odour	0
1	Slight	0.013
2	Definite	0.053
3	Moderate	0.22
4	Strong	0.87

5	Very Strong	3.57

Average scores for each test product and the control product were then determined and the score for each test product was subtracted from the score for the control product to give the Odour Reduction Value.

Average panel score perfume A	2.08
Control panel score	2.31
Odour Reduction Value perfume A	0.23
Odour Reduction Value as percentage of control score	10%

Difference for significance @95% 0.21
Difference for significance @99% 0.28

Average panel score perfume B	1.98
Control panel score	2.31
Odour Reduction Value perfume B	0.33
Odour Reduction Value as percentage of control score	14%

Difference for significance @ 95% 0.21
Difference for significance @ 99% 0.28

Perfume A contained 47.5% and perfume B contained 54% of active perfume components.

CLAIMS

1. A cosmetic method for reducing or preventing body malodour by topically applying to human skin a composition comprising an active agent capable of inactivating body malodour-causing micro-organisms comprising corynebacteria, wherein the agent is a perfume component which is capable of inactivating the corynebacteria capable of catabolising fatty acids.

2. A method according to claim 1 wherein the composition is a perfume composition comprising at least 30% by weight of one or more of the perfume components capable of inactivating the corynebacteria capable of catabolising fatty acids.

3. A method according to either one of claims 1 and 2 wherein the perfume component comprises at least one of the following materials (Z)-3,4,5,6,6-pentamethylhept-3-en-2-one, mixtures of diethyl- and dimethyl-cyclohex-2-en-1-one, citronellol, 2-methyl-3-(4-(1-methylethyl)phenyl)propanal, (2-(methyloxy)-4-propyl-1-benzenol), diphenylmetnane, tetrahydrolinalol, 4-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(4-methyl-3-pentenyl)cyclohex -3-ene-1-carbaldehyde, 3-(1,3-benzodioxol -5-yl)-2-methylpropanal, α-ionone, β-ionone, tricyclo[5.2.1.0,2,6]dec-4-en-8-yl ethanoate, 4-(4-hydroxy-4-methylpentyl)cyclohex -3-enecarbaldehyde, 3-(4-hydroxy-4-methylpentyl)- cyclohex-3-enecarbaldehyde, methyl iso-eugenol, 2-(1,1-dimethylethyl)cyclohexyl ethanoate, 4-(1,1-dimethylethyl)cyclohexyl ethanoate, 4-methyl-2-(2-methylprop-1-enyl)tetrahydropyran.

4. A method according to any one of the preceding claims wherein an Odour Reduction Value of at least 10% is obtained.

5. A method according to any one of the preceding claims wherein the perfume component inactivates the corynebacteria capable of catabolising fatty acids.

6. The use of a perfume component to inactivate the corynebacteria capable of catabolising fatty acids.

7. The use of a perfume composition, comprising at least 30% by weight of one or more perfume components capable of inactivating the corynebacteria capable of catabolising fatty acids, to reduce body malodour.

8. The use of a deodorant product, comprising a perfume component, to reduce body malodour by inactivating the corynebacteria capable of catabolising fatty acids.

9. A perfume composition comprising at least 30% by weight of one or more of the perfume components listed in claim 3.

10. A deodorant product comprising a perfume composition defined in claim 9.

11. A method of producing a perfume composition which comprises (i) evaluating perfume components on the ability to inhibit fatty acid metabolism in corynebacteria, (ii) selecting perfume components on the ability to sub-lethally inhibit fatty acid metabolism in corynebacteria, and (iii) mixing together two or more of said selected perfume components, optionally with other perfume components.

12. A method according to claim 11 wherein the selected perfume components are one or more of the perfume components listed in claim 3.

13. A perfume composition comprising at least 30% by weight of one or more of the following perfume components;
(Z)-3,4,5,6,6-pentamethylhept-3-en-2-one, mixtures of diethyl- and dimethyl- cyclohex-2-en-1-one, 2-methyl-3-(4-(1-methylethyl)phenyl)propanal, (2-(methyloxy)-4-propyl-1-benzenol), diphenylmethane, tetrahydrolinalol, 4-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, α-ionone, β-ionone, tricyclo[5.2.1.0,2,6]dec-4-en-8-yl ethanoate, 4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde, 3-(4-hydroxy-4-methylpentyl)-cyclohex-3-enecarbaldehyde, methyl iso-eugenol, 2-(1,1-dimethylethyl)cyclohexyl ethanoate, 4-(1,1-dimethylethyl)cyclohexyl ethanoate, 4-methyl-2-(2-methylprop-1-enyl)tetrahydropyran.

14. A perfume composition comprising at least 60% by weight of one or more of the following perfume components;
(Z)-3,4,5,6,6-pentamethylhept-3-en-2-one, mixtures of diethyl- and dimethyl- cyclohex-2-en-1-one, citronellol, 2-methyl-3-(4-(1-methylethyl)phenyl)propanal, (2-(methyloxy)-4-propyl-1-benzenol), diphenylmethane, tetrahydrolinalol, 4-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, α-ionone, β-ionone, tricyclo[5.2.1.0,2,6]dec-4-en-8-yl ethanoate, 4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde, 3-(4-hydroxy-4-methylpentyl)-cyclohex-3-enecarbaldehyde, methyl iso-eugenol, 2-(1,1-dimethylethyl)cyclohexyl ethanoate, 4-(1,1-dimethylethyl)cyclohexyl ethanoate, 4-methyl-2-(2-methylprop-1-enyl)tetrahydropyran.

15. A perfume composition comprising at least 30% by weight of at least 5 of the following perfume components;
(Z)-3,4,5,6,6-pentamethylhept-3-en-2-one, mixtures of diethyl- and dimethyl- cyclohex-2-en-1-one, citronellol, 2-methyl-3-(4-(1-methylethyl)phenyl)propanal, (2-(methyloxy)-4-propyl-1-benzenol), diphenylmethane, tetrahydrolinalol, 4-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(4-methyl-3-pentenyl)cyclohex-3-ene-1-carbaldehyde, 3-(1,3-benzodioxol-5-yl)-2-methylpropanal, α-ionone, β-ionone, tricyclo[5.2.1.0,2,6]dec-4-en-8-yl ethanoate, 4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde, 3-(4-hydroxy-4-methylpentyl)-cyclohex-3-enecarbaldehyde, methyl iso-eugenol, 2-(1,1-dimethylethyl)cyclohexyl ethanoate, 4-(1,1-dimethylethyl)cyclohexyl ethanoate, 4-methyl-2-(2-methylprop-1-enyl)tetrahydropyran.

AMENDED SHEET

C90-041Q

FOR UTILITY/DESIGN
CIP/PCT NATIONAL/PLANT
ORIGINAL/SUBSTITUTE/SUPPLEMENTAL
DECLARATIONS

RULE 63 (37 C.F.R. 1.63) DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PM & S FORM

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the INVENTION ENTITLED : METHOD OF REDUCING OR PREVENTING MALODOUR

the specification of which (CHECK applicable BOX(ES))

X BOX(ES) →
A. ☐ is attached hereto.
→ B. ☐ was filed on _____ as U.S. Application No. ____/____
→ C. ☐ was filed as PCT International Application No. PCT/ ____/____ on _____

and (if applicable to U.S. or PCT application) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56. Except as noted below, I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT International Application which designated at least one other country than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International Application, filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing date of this application:

PRIOR FOREIGN APPLICATION(S) Number	Country	Day/MONTH/Year Filed	Date first Laid-open or Published	Date Patented or Granted	Priority NOT Claimed
9814653.3	Great Britain	07/July/1998			

If more prior foreign applications, X box *at bottom* and continue on attached page.

Except as noted below, I hereby claim domestic priority benefit under 35 U.S.C. 119(e) or 120 and/or 365(c) of the indicated United States applications listed below and PCT international applications listed above or below and, if this is a continuation-in-part (CIP) application, insofar as the subject matter disclosed and claimed in this application is in addition to that disclosed in such prior applications, I acknowledge the duty to disclose all information known to me to be material to patentability as defined in 37 C.F.R. 1.56 which became available between the filing date of each such prior application and the national or PCT international filing date of this application:

PRIOR U.S. PROVISIONAL, NONPROVISIONAL AND/OR PCT APPLICATION(S) Application No. (series code/serial no.)	Day/MONTH/Year Filed	Status pending, abandoned, patented	Priority NOT Claimed
PCT/GB99/02165	06/July/1999		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

And I hereby appoint Pillsbury Madison & Sutro LLP, Intellectual Property Group, 1100 New York Avenue, N.W., Ninth Floor, East Tower, Washington, D.C. 20005-3918, telephone number (202) 861-3000 (to whom all communications are to be directed), and the below-named persons (of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent, and I hereby authorize them to delete names/numbers below of persons no longer with their firm and to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct the above Firm and/or a below attorney in writing to the contrary.

Paul N. Kokulis	16773	Paul E. White, Jr.	32011	Stephen C. Glazier	31361	William P. Atkins	38821
Raymond F. Lippitt	17519	Glenn J. Perry	28458	Ruth N. Morduch	31044	Paul L. Sharer	36004
G. Lloyd Knight	17698	Kendrew H. Colton	30368	Richard H. Zaitlen	27248	Robin L. Teskin	35030
Kevin E. Joyce	20508	G. Paul Edgell	24238	Roger R. Wise	31204		
George M. Sirilla	18221	Lynn E. Eccleston	35861	Michael R. Dzwonczyk	36787		
Donald J. Bird	25323	Timothy J. Klima	34852	W. Patrick Bengtsson	32456		
Peter W. Gowdey	25872	David A. Jakopin	32995	Jack S. Barufka	37087		
Dale S. Lazar	28872	Mark G. Paulson	30793	Adam R. Hess	41835		

(1) INVENTOR'S SIGNATURE: Craig Wilson Date: 19/12/2000

Craig	S.	WILSON
First	Middle Initial	Family Name
Residence: Kent	Great Britain GB3	Great Britain
City	State/Foreign Country	Country of Citizenship
Mailing Address: 30 Tilden Close, High Halden, Kent, Great Britain		
(include Zip Code): TN26 3LR		

(2) INVENTOR'S SIGNATURE: Tony Minhas Date: 20/12/2000

Tony		MINHAS
First	Middle Initial	Family Name
Residence: Kent	Great Britain GB3	Great Britain
City	State/Foreign Country	Country of Citizenship
Mailing Address: 30 King Edward Avenue, Dartford, Kent, Great Britain		
(include Zip Code): DA1 2HZ		

"X" box ☒ FOR ADDITIONAL INVENTORS, and proceed on the attached page to list each additional inventor.
☐ See additional foreign priorities on attached page (incorporated herein by reference).

Atty. Dkt. No. PM275443
(M#)

DECLARATION AND POWER OF ATTORNEY
(continued)
ADDITIONAL INVENTORS:

(3) **INVENTOR'S SIGNATURE:** John Martin Behan **Date:** 19.12.2000

John	M.	BEHAN	
First	Middle Initial	Family Name	
Residence: Kent	Great Britain GBR 3	Great Britain	
City	State/Foreign Country	Country of Citizenship	
Mailing Address (include Zip Code): The Forge, The Green, Boughton Aluph, Ashford, Kent, Great Britain TN25 4JB			

(4) **INVENTOR'S SIGNATURE:** **Date:**

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Mailing Address (include Zip Code)			

(5) **INVENTOR'S SIGNATURE:** **Date:**

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Mailing Address (include Zip Code)			

(6) **INVENTOR'S SIGNATURE:** **Date:**

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Mailing Address (include Zip Code)			

(7) **INVENTOR'S SIGNATURE:** **Date:**

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Mailing Address (include Zip Code)			

(8) **INVENTOR'S SIGNATURE:** **Date:**

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Mailing Address (include Zip Code)			

(9) **INVENTOR'S SIGNATURE:** **Date:**

First	Middle Initial	Family Name	
Residence			
City	State/Foreign Country	Country of Citizenship	
Mailing Address (include Zip Code)			